Thymosin beta-4
Tβ4 / Tbeta4 / RGN-259
- Peptide length
- 43 amino acids
Full-length peptide
Open the sources to check how the studies were done and what they can support.
A naturally occurring actin-binding peptide with formulation-specific human research, including ophthalmic studies.
- Family
- Actin-binding peptide
- Research target
- Actin-associated cellular pathways
- Molecular form
- Full-length peptide
What to know about the research
In the 72-person dry-eye trial, neither primary endpoint differed significantly from placebo. Some secondary endpoints improved. These ophthalmic findings do not establish benefit for systemic preparations or TB-500 fragments.
Check the exact compound
Keep the 43-residue parent distinct from N-acetylated LKKTETQ sold as TB-500. Terminal modifications and formulation also matter.
What supports this entry?
3 of 3 summary statements linked to checked source passages.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
Check the overview statementSource checked
A naturally occurring actin-binding peptide with formulation-specific human research, including ophthalmic studies.
Abstract: Methods and Results; full-text Introduction for 43-residue identity
Full-text Introduction: 43-amino-acid actin-binding peptide
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Check the evidence limitationSource checked
In the 72-person dry-eye trial, neither primary endpoint differed significantly from placebo. Some secondary endpoints improved. These ophthalmic findings do not establish benefit for systemic preparations or TB-500 fragments.
Abstract: Methods and Results; full-text Introduction for 43-residue identity
Abstract: exact studied material and setting; separate parent/fragment scope
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Check the identity statementSource checked
Keep the 43-residue parent distinct from N-acetylated LKKTETQ sold as TB-500. Terminal modifications and formulation also matter.
Abstract: Methods and Results; full-text Introduction for 43-residue identity
Full-text Introduction: 43-amino-acid actin-binding peptide
Abstract: exact studied material and setting; separate parent/fragment scope
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Inside the selected studies
Phase II randomized, double-masked, placebo-controlled trial
RGN-259 thymosin beta-4 ophthalmic solution
- Who or what was studied
- Participants with moderate to severe dry eye
- Sample size
- 72
- Compared with
- Placebo
- Duration
- 28 days of treatment; primary endpoints on day 29
- No significant difference in either primary endpoint.
- Selected secondary endpoints showed improvements.
- Selected study only; source mapping is not independent study-quality appraisal.
- The finding applies to this population, preparation and study design.